Loading clinical trials...
Loading clinical trials...
A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of the Materna Prep Device to Pre-stretch the Vaginal Canal and Pelvic Floor Tissues in Preparation for Vaginal Delivery
This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery. Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor. Subject participation in the study is targeted to be 12 months from the time of the use of the device during delivery.
Vaginal delivery is a major risk factor for pelvic floor dysfunction. Clinical aspects of pelvic floor dysfunction include pelvic organ prolapse, sexual dysfunction, and fecal and urinary incontinence. Trauma to the pelvic structures occurs as the fetal head passes through the vaginal canal, especially with acute distension at the time of crowning - the exiting of the fetal head. The Materna Prep Device is a single-use, semi-automated dilator used during the first phase of labor in order to prepare the vaginal canal for vaginal delivery. By slowly pre-stretching the vagina and surrounding pelvic tissues during labor, the device is essentially dictating the strain rate of the tissue during labor. In previous feasibility studies, the elastic recovery of the tissue has been shown to be on the order of several hours, allowing the benefits of pre-stretching the vagina and surrounding pelvic tissues to last throughout labor. The device is intended to be removed prior to the initiation of the second stage of labor, for delivery to occur unobstructed. The target patient population for this study is nulliparous women entering the first phase of labor and scheduled for vaginal delivery with an epidural.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
University of Alabama at Birmingham
Birmingham, Alabama, United States
La Follette Ob/Gyn
Greenbrae, California, United States
University of California Los Angeles
Los Angeles, California, United States
El Camino Hospital
Mountain View, California, United States
Christiana Care - Center for Women's & Children's Health
Newark, Delaware, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
USF Ob/Gyn
Tampa, Florida, United States
The Healing Sanctuary
Idaho Falls, Idaho, United States
Mayo Clinic
Rochester, Minnesota, United States
The Cooper Health System
Camden, New Jersey, United States
Start Date
December 11, 2019
Primary Completion Date
July 30, 2026
Completion Date
August 30, 2026
Last Updated
September 17, 2025
420
ACTUAL participants
Materna Prep Device
DEVICE
Standard of Care (SOC)
OTHER
Lead Sponsor
Materna Medical
Collaborators
NCT05602246
NCT05042453
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06568289